Leveraging the Brain’s Sugar Transport Channel: Mannose Nanoparticles Extend Survival by 50% in Mice With Brain Cancer

Glioblastoma is difficult to treat not only because tumors grow rapidly and readily recur, but also because the blood–brain barrier keeps many drugs out of the brain. A study published in the *Journal of Controlled Release* attempted to turn this defense into a transport gateway: lipid nanoparticles coated with mannose were used to deliver messenger RNA for a tumor-suppressor gene into brain tumors.

The design uses the glucose transporter GLUT1. It normally helps glucose cross the endothelial cells of blood vessels in the brain and can also recognize mannose, which has a structure similar to glucose. The research team attached mannose directly to the cholesterol component of the nanoparticles, increasing surface coverage by approximately sixfold and producing a mannose density of about 30 mol%, thereby improving their ability to compete for GLUT1 transport in the high-glucose environment of the bloodstream.

The same gateway also serves as a second layer of navigation. The research team noted that GLUT1 expression in glioblastoma tissue is approximately three times that in normal brain tissue, making the particles more likely to accumulate in tumors after crossing the blood–brain barrier. Animal experiments showed that this formulation accumulated in the brain at approximately 9.9 times the level of untargeted particles, indicating the possibility of using a single ligand to address both “entering the brain” and “approaching cancer cells.”

The nanoparticles carry messenger RNA encoding the PTEN protein. PTEN is an important tumor-suppressor protein that limits cell proliferation but is often missing or loses its function in glioblastoma. Rather than permanently rewriting DNA, the strategy temporarily provides instructions for producing PTEN. The formulation achieved a messenger RNA encapsulation rate of more than 90% and incorporated a positively charged cholesterol derivative to reduce cargo loss or degradation during delivery.

After treatment with PTEN messenger RNA, the mice’s tumor burden fell to approximately one-sixth, while median survival increased from 33 days to 49 days, an improvement of nearly 50%. During repeated dosing, the researchers observed tumor shrinkage and detected no obvious toxicity in the organs examined. These results support that the delivery mechanism functioned as intended, but they do not amount to proof that it is safe or effective in humans.

The real test will come from longer-term, more diverse animal studies and eventual human trials. Whether blood glucose levels affect competition between the particles and glucose, differences in GLUT1 and PTEN among patients’ tumors, immune responses to repeated injections, dosage, and manufacturing consistency are all questions that must be answered before translation. The research team also estimates that the technology will still require years of safety and efficacy testing. At this stage, it should be regarded as early-stage brain cancer delivery research with a mechanistic basis, rather than a therapy available to patients.